IL102963A0 - Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus - Google Patents
Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virusInfo
- Publication number
- IL102963A0 IL102963A0 IL102963A IL10296392A IL102963A0 IL 102963 A0 IL102963 A0 IL 102963A0 IL 102963 A IL102963 A IL 102963A IL 10296392 A IL10296392 A IL 10296392A IL 102963 A0 IL102963 A0 IL 102963A0
- Authority
- IL
- Israel
- Prior art keywords
- peptides
- hbv
- hepatitis
- virus
- lymphocyte responses
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 101710150451 Protein Bel-1 Proteins 0.000 abstract 1
- 101710086987 X protein Proteins 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74954091A | 1991-08-26 | 1991-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL102963A0 true IL102963A0 (en) | 1993-01-31 |
Family
ID=25014174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL102963A IL102963A0 (en) | 1991-08-26 | 1992-08-26 | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0534618B1 (bg) |
| JP (3) | JP3566284B2 (bg) |
| AT (1) | ATE320444T1 (bg) |
| AU (1) | AU679901B2 (bg) |
| BG (1) | BG98522A (bg) |
| CA (1) | CA2115927C (bg) |
| CZ (1) | CZ42894A3 (bg) |
| DE (1) | DE69233607T2 (bg) |
| DK (1) | DK0534618T3 (bg) |
| ES (1) | ES2262132T3 (bg) |
| FI (1) | FI940919A (bg) |
| HU (1) | HUT67529A (bg) |
| IL (1) | IL102963A0 (bg) |
| NO (1) | NO940661L (bg) |
| NZ (2) | NZ244102A (bg) |
| OA (1) | OA09889A (bg) |
| PT (1) | PT534618E (bg) |
| WO (1) | WO1993003753A1 (bg) |
| ZA (1) | ZA926440B (bg) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| US6607727B1 (en) | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
| US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| EP1704868A1 (en) * | 1992-08-07 | 2006-09-27 | Pharmexa Inc. | HLA binding peptides and their uses |
| US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| DK17093D0 (da) * | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
| ATE227118T1 (de) * | 1993-08-02 | 2002-11-15 | Scripps Research Inst | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
| GB9325772D0 (en) * | 1993-12-16 | 1994-02-16 | Smithkline Beecham Biolog | Novel compounds |
| EP1049711B1 (en) * | 1998-01-19 | 2003-12-10 | Mogam Biotechnology Research Institute | Liposomes comprising peptide antigens derived from x protein of hepatitis b virus |
| US20010019714A1 (en) * | 1998-04-07 | 2001-09-06 | Charles D. Y. Sia | Hiv-specific cytotoxic t-cell responses |
| US7105164B1 (en) | 1998-04-07 | 2006-09-12 | Sanofi Pasteur Limited | HIV-specific cytotoxic T-cell responses |
| GB0328753D0 (en) * | 2003-12-11 | 2004-01-14 | Royal Veterinary College The | Hepatitis B vaccines |
| WO2010086294A2 (en) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| JP2017525681A (ja) * | 2014-07-22 | 2017-09-07 | アリオス バイオファーマ インク． | パラミクソウイルスの治療方法 |
| KR20230030032A (ko) | 2016-06-20 | 2023-03-03 | 아이에스에이 파마슈티컬즈 비.브이. | 펩타이드 백신의 제형 |
| US20230087348A1 (en) * | 2019-01-11 | 2023-03-23 | Agency For Science, Technology And Research | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4939900A (bg) * | 1972-08-25 | 1974-04-13 | ||
| US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| GB9016727D0 (en) * | 1990-07-31 | 1990-09-12 | Clonit Spa | Amino acid residue sequence of hepatitis b core antigen |
-
1992
- 1992-08-26 NZ NZ244102A patent/NZ244102A/en not_active IP Right Cessation
- 1992-08-26 PT PT92307785T patent/PT534618E/pt unknown
- 1992-08-26 EP EP92307785A patent/EP0534618B1/en not_active Expired - Lifetime
- 1992-08-26 ES ES92307785T patent/ES2262132T3/es not_active Expired - Lifetime
- 1992-08-26 AT AT92307785T patent/ATE320444T1/de active
- 1992-08-26 DK DK92307785T patent/DK0534618T3/da active
- 1992-08-26 CA CA002115927A patent/CA2115927C/en not_active Expired - Lifetime
- 1992-08-26 WO PCT/US1992/007213 patent/WO1993003753A1/en not_active Application Discontinuation
- 1992-08-26 IL IL102963A patent/IL102963A0/xx unknown
- 1992-08-26 CZ CS94428A patent/CZ42894A3/cs unknown
- 1992-08-26 HU HU9400582A patent/HUT67529A/hu unknown
- 1992-08-26 ZA ZA926440A patent/ZA926440B/xx unknown
- 1992-08-26 AU AU25408/92A patent/AU679901B2/en not_active Ceased
- 1992-08-26 JP JP50466293A patent/JP3566284B2/ja not_active Expired - Lifetime
- 1992-08-26 DE DE69233607T patent/DE69233607T2/de not_active Expired - Lifetime
-
1994
- 1994-02-22 BG BG98522A patent/BG98522A/bg unknown
- 1994-02-25 NO NO940661A patent/NO940661L/no unknown
- 1994-02-25 FI FI940919A patent/FI940919A/fi unknown
- 1994-02-25 OA OA60476A patent/OA09889A/en unknown
-
1995
- 1995-03-03 NZ NZ270625A patent/NZ270625A/en not_active IP Right Cessation
-
2003
- 2003-02-20 JP JP2003043002A patent/JP3694299B2/ja not_active Expired - Fee Related
- 2003-02-20 JP JP2003043036A patent/JP3694300B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003267997A (ja) | 2003-09-25 |
| EP0534618A3 (en) | 1993-06-30 |
| HUT67529A (en) | 1995-04-28 |
| EP0534618A2 (en) | 1993-03-31 |
| JP3694299B2 (ja) | 2005-09-14 |
| NO940661D0 (no) | 1994-02-25 |
| JP3694300B2 (ja) | 2005-09-14 |
| FI940919A0 (fi) | 1994-02-25 |
| FI940919A (fi) | 1994-04-25 |
| WO1993003753A1 (en) | 1993-03-04 |
| EP0534618B1 (en) | 2006-03-15 |
| AU679901B2 (en) | 1997-07-17 |
| CA2115927A1 (en) | 1993-03-04 |
| ZA926440B (en) | 1993-06-07 |
| ATE320444T1 (de) | 2006-04-15 |
| AU2540892A (en) | 1993-03-16 |
| CZ42894A3 (en) | 1995-02-15 |
| JP2003300999A (ja) | 2003-10-21 |
| NO940661L (no) | 1994-04-19 |
| ES2262132T3 (es) | 2006-11-16 |
| PT534618E (pt) | 2006-08-31 |
| OA09889A (en) | 1994-09-15 |
| BG98522A (bg) | 1995-05-31 |
| NZ244102A (en) | 1996-12-20 |
| HU9400582D0 (en) | 1994-07-28 |
| NZ270625A (en) | 1996-12-20 |
| DE69233607D1 (de) | 2006-05-11 |
| DK0534618T3 (da) | 2006-07-24 |
| JP3566284B2 (ja) | 2004-09-15 |
| DE69233607T2 (de) | 2006-11-30 |
| CA2115927C (en) | 2009-04-21 |
| JPH06510050A (ja) | 1994-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0534618A3 (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
| EP0726758A4 (en) | PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTHES TARGETED AGAINST THE HEPATITIS B-VIRUS | |
| EP0687182A4 (en) | PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTES AGAINST THE HEPATITIS B VIRUS | |
| EP1018344A3 (en) | HLA-restricted hepatitis B virus CTL epitopes | |
| ATE322903T1 (de) | Diätzusatz zur behandlung von malignitäten und virusinfektionen und verbesserung der immunfunktion | |
| Kaplan et al. | Pathogenesis of rabies in immunodeficient mice | |
| Mifune et al. | Essential role of T cells in the postexposure prophylaxis of rabies in mice | |
| Harmon et al. | Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines | |
| DE69428112D1 (de) | Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen | |
| RU94032103A (ru) | Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации | |
| RU94038427A (ru) | Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации | |
| CA2156416A1 (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
| ATE111485T1 (de) | Peptidbehandlung von hartnäckigen infektionskrankheiten. | |
| DK0542895T3 (da) | Krydsreaktiv influenza A immunisering | |
| Zourbas et al. | Immunization of dental surgeons against hepatitis B virus infection. | |
| 朱启镕 et al. | LONG-TERM IMMUNOGENICITY AND EFFICACY OF RECOMBINANT YEAST DERIVED HEPATITIS B VACCINE FOR INTERRUPTION OF MOTHER-INFANT TRANSMISSION OF HEPATITIS B VIRUS |